Literature DB >> 25446769

Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance.

David J Mc Carthy1, Meenakshi Malhotra, Aoife M O'Mahony, John F Cryan, Caitriona M O'Driscoll.   

Abstract

The blood-brain barrier is a unique cell-based restrictive barrier that prevents the entry of many substances, including most therapeutics, into the central nervous system. A wide range of nanoparticulate delivery systems have been investigated with the aim of targeting therapeutics (drugs, nucleic acids, proteins) to the brain following administration by various routes. This review provides a comprehensive description of the design and formulation of these nanoparticles including the rationale behind individual approaches. In addition, the ability of currently available in-vitro BBB models to accurately predict the in-vivo performance of targeted nanoparticles is critically assessed.

Mesh:

Substances:

Year:  2014        PMID: 25446769     DOI: 10.1007/s11095-014-1545-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  204 in total

Review 1.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

Authors:  David J Begley
Journal:  Pharmacol Ther       Date:  2004-10       Impact factor: 12.310

2.  Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells.

Authors:  Yadollah Omidi; Jaleh Barar; Somaieh Ahmadian; Hamid Reza Heidari; Mark Gumbleton
Journal:  Cell Biochem Funct       Date:  2008-04       Impact factor: 3.685

Review 3.  The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier.

Authors:  Eugen Barbu; Eva Molnàr; John Tsibouklis; Dariusz C Górecki
Journal:  Expert Opin Drug Deliv       Date:  2009-06       Impact factor: 6.648

4.  Uptake and transport of superparamagnetic iron oxide nanoparticles through human brain capillary endothelial cells.

Authors:  L B Thomsen; T Linemann; K M Pondman; J Lichota; K S Kim; R J Pieters; G M Visser; T Moos
Journal:  ACS Chem Neurosci       Date:  2013-08-26       Impact factor: 4.418

5.  Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells.

Authors:  Eleni Markoutsa; Konstantina Papadia; Carla Clemente; Orfeu Flores; Sophia G Antimisiaris
Journal:  Eur J Pharm Biopharm       Date:  2012-02-22       Impact factor: 5.571

6.  In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes.

Authors:  Yao Qin; Wei Fan; Huali Chen; Nian Yao; Wenwei Tang; Jie Tang; Wenmin Yuan; Rui Kuai; Zhirong Zhang; Yong Wu; Qin He
Journal:  J Drug Target       Date:  2010-08       Impact factor: 5.121

Review 7.  Active targeting of brain tumors using nanocarriers.

Authors:  Arnaud Béduneau; Patrick Saulnier; Jean-Pierre Benoit
Journal:  Biomaterials       Date:  2007-08-22       Impact factor: 12.479

8.  Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins.

Authors:  Antonio Fittipaldi; Aldo Ferrari; Monica Zoppé; Caterina Arcangeli; Vittorio Pellegrini; Fabio Beltram; Mauro Giacca
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

9.  Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.

Authors:  Xue Ying; He Wen; Wan-Liang Lu; Ju Du; Jia Guo; Wei Tian; Ying Men; Yan Zhang; Ruo-Jing Li; Ting-Yuan Yang; De-Wei Shang; Jin-Ning Lou; Liang-Ren Zhang; Qiang Zhang
Journal:  J Control Release       Date:  2009-09-30       Impact factor: 9.776

10.  Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance.

Authors:  Adjanie Patabendige; Robert A Skinner; N Joan Abbott
Journal:  Brain Res       Date:  2012-07-10       Impact factor: 3.252

View more
  34 in total

Review 1.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

2.  Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.

Authors:  Uday K Sukumar; Rajendran J C Bose; Meenakshi Malhotra; Husam A Babikir; Rayhaneh Afjei; Elise Robinson; Yitian Zeng; Edwin Chang; Frezghi Habte; Robert Sinclair; Sanjiv S Gambhir; Tarik F Massoud; Ramasamy Paulmurugan
Journal:  Biomaterials       Date:  2019-07-12       Impact factor: 12.479

3.  In vitro models of molecular and nano-particle transport across the blood-brain barrier.

Authors:  Cynthia Hajal; Marco Campisi; Clara Mattu; Valeria Chiono; Roger D Kamm
Journal:  Biomicrofluidics       Date:  2018-05-31       Impact factor: 2.800

4.  Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation.

Authors:  Eiji Saito; Robert Kuo; Ryan M Pearson; Nishant Gohel; Brandon Cheung; Nicholas J C King; Stephen D Miller; Lonnie D Shea
Journal:  J Control Release       Date:  2019-02-27       Impact factor: 9.776

5.  Toxicological Aspects of Iron Oxide Nanoparticles.

Authors:  Natalia Fernández-Bertólez; Carla Costa; Fátima Brandão; João Paulo Teixeira; Eduardo Pásaro; Vanessa Valdiglesias; Blanca Laffon
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 6.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

Review 7.  Walking the line: The fate of nanomaterials at biological barriers.

Authors:  Huan Meng; Wei Leong; Kam W Leong; Chunying Chen; Yuliang Zhao
Journal:  Biomaterials       Date:  2018-05-05       Impact factor: 12.479

Review 8.  Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan.

Authors:  Miguel Moreno; Ernest Giralt
Journal:  Toxins (Basel)       Date:  2015-04-01       Impact factor: 4.546

Review 9.  Therapeutic benefits of nanoparticles in stroke.

Authors:  Stavros Panagiotou; Sikha Saha
Journal:  Front Neurosci       Date:  2015-05-19       Impact factor: 4.677

10.  Improving the Delivery of SOD1 Antisense Oligonucleotides to Motor Neurons Using Calcium Phosphate-Lipid Nanoparticles.

Authors:  Liyu Chen; Clare Watson; Marco Morsch; Nicholas J Cole; Roger S Chung; Darren N Saunders; Justin J Yerbury; Kara L Vine
Journal:  Front Neurosci       Date:  2017-08-30       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.